{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T14:39:53Z","timestamp":1747147193208,"version":"3.40.5"},"reference-count":45,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T00:00:00Z","timestamp":1680048000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To investigate the differences in efficacy and safety between haploidentical donor hematopoietic stem cell transplantation (HID\u2010HSCT) and matched sibling donor HSCT (MSD\u2010HSCT) in patients with T\u2010cell lymphoblastic lymphoma (T\u2010LBL).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this retrospective analysis, we enrolled 38 patients who had undergone allogeneic HSCT at our institution between 2013 and 2021. The study participants included 28 patients who underwent HID\u2010HSCT and 10 patients who underwent MSD\u2010HSCT. We compared the patient characteristics and treatment effectiveness and safety between the two groups and evaluated potential prognostic variables for patients with T\u2010LBL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The median follow\u2010up durations in the HID\u2010HSCT and MSD\u2010HSCT groups were 23.5 (range: 4\u2013111) and 28.5 (range: 13\u201356) months, respectively. All patients showed full\u2010donor chimerism after hematopoietic stem cell transplantation (HSCT). Except for two patients in the HID\u2010HSCT cohort who developed poor graft function, all patients showed neutrophil and platelet engraftments after HSCT. The cumulative incidences of grades III\u2013IV acute graft\u2010versus\u2010host disease were 37.5% and 28.57% in the HID\u2010HSCT and MSD\u2010HSCT groups, respectively (<jats:italic>p<\/jats:italic>\u2009=\u20090.84). The cumulative incidences of limited (34.13% vs. 28.57%, <jats:italic>p<\/jats:italic>\u2009=\u20090.82) and extensive (31.22% vs. 37.50%, <jats:italic>p<\/jats:italic>\u2009=\u20090.53) chronic graft\u2010versus\u2010host disease did not differ between the two cohorts. In the HID\u2010HSCT and MSD\u2010HSCT cohorts, the estimated 2\u2010year overall survival rates were 70.3% (95% confidence interval [CI]: 54.9%\u201390.0%) and 56.2% (95% CI: 31.6%\u2013100%), respectively (<jats:italic>p<\/jats:italic>\u2009=\u20091.00), and the estimated 2\u2010year progression\u2010free survival (PFS) rates were 48.5% (95% CI: 32.8%\u201371.6%) and 48.0% (95% CI: 24.6%\u201393.8%), respectively (<jats:italic>p<\/jats:italic>\u2009=\u20090.94). Furthermore, the Cox proportional\u2010hazards model showed that a positive positron emission tomography\/computed tomography (PET\/CT) status before HSCT in patients who had completed chemotherapy was an independent risk factor for PFS in the multivariate analysis (<jats:italic>p<\/jats:italic>\u2009=\u20090.0367).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study showed that HID\u2010HSCT had comparable effectiveness and safety to MSD\u2010HSCT in treating T\u2010LBL. HID\u2010HSCT could serve as an alternate treatment option for T\u2010LBL in patients without an eligible identical donor. Achievement of the PET\/CT\u2010negative status before HSCT may contribute to better survival.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.5786","type":"journal-article","created":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T05:17:13Z","timestamp":1680153433000},"page":"10499-10511","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of efficacies of haploidentical transplantation and matched sibling donor transplantation in treating T\u2010cell lymphoblastic lymphoma"],"prefix":"10.1002","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9852-5010","authenticated-orcid":false,"given":"Ruowen","family":"Wei","sequence":"first","affiliation":[{"name":"Institute of Hematology, Union Hospital, Tongji Medical College Huazhong University of Science and Technology  Wuhan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9634-3319","authenticated-orcid":false,"given":"Jun","family":"Fang","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Union Hospital, Tongji Medical College Huazhong University of Science and Technology  Wuhan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Shi","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Union Hospital, Tongji Medical College Huazhong University of Science and Technology  Wuhan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Lu","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Union Hospital, Tongji Medical College Huazhong University of Science and Technology  Wuhan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingying","family":"Wu","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Union Hospital, Tongji Medical College Huazhong University of Science and Technology  Wuhan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Union Hospital, Tongji Medical College Huazhong University of Science and Technology  Wuhan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Union Hospital, Tongji Medical College Huazhong University of Science and Technology  Wuhan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanshan","family":"Liao","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Union Hospital, Tongji Medical College Huazhong University of Science and Technology  Wuhan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunxia","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Union Hospital, Tongji Medical College Huazhong University of Science and Technology  Wuhan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guohui","family":"Cui","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Union Hospital, Tongji Medical College Huazhong University of Science and Technology  Wuhan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7286-3062","authenticated-orcid":false,"given":"Linghui","family":"Xia","sequence":"additional","affiliation":[{"name":"Institute of Hematology, Union Hospital, Tongji Medical College Huazhong University of Science and Technology  Wuhan China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,3,29]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14017"},{"volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","year":"2008","author":"Swerdlow SH","key":"e_1_2_9_3_1"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2017.03.020"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-89-3-319"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19811201)48:11<2347::AID-CNCR2820481102>3.0.CO;2-X"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810515)47:10<2510::AID-CNCR2820471034>3.0.CO;2-8"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V57.1.186.186"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4428"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.828350"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.5385"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-05-1483"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2258-y"},{"issue":"19","key":"e_1_2_9_14_1","first-page":"2646","article-title":"A randomized phase 3 trial of autologous vs. allogeneic transplantation as part of first\u2010line therapy in poor\u2010risk peripheral T\u2010NHL","volume":"137","author":"Schmitz N","year":"2021","journal-title":"Blood"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf010"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2013.20"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01159-2"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2335"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14854"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01065-7"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.12659\/AOT.909122"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1775205"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2011.66"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1988.6.10.1562"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2016.04.014"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1159\/000441507"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2440-x"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-197410000-00001"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197504242921706"},{"issue":"6","key":"e_1_2_9_32_1","first-page":"825","article-title":"1994 consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka D","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.12.001"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2013.855816"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000011374"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2005.07.001"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-78334-x"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1193860"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2021.106627"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0943-1"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620720948743"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.05.036"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.02.020"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4353"},{"key":"e_1_2_9_45_1","article-title":"Post\u2010transplantation Fluorine\u201018 fluorodeoxyglucose positron emission tomography in patients with lymphoblastic lymphoma is an independent prognostic factor with an impact on progression\u2010free survival but not overall survival","volume":"20","author":"Dai N","year":"2021","journal-title":"Technol Cancer Res Treat"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-021-02551-7"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.5786","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T07:01:53Z","timestamp":1714806113000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.5786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,29]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1002\/cam4.5786"],"URL":"https:\/\/doi.org\/10.1002\/cam4.5786","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"type":"print","value":"2045-7634"},{"type":"electronic","value":"2045-7634"}],"subject":[],"published":{"date-parts":[[2023,3,29]]},"assertion":[{"value":"2022-09-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}